gabapentin strides 400 mg kapseli, kova
strides pharma (cyprus) limited - gabapentin - kapseli, kova - 400 mg - gabapentiini
gabapentin strides 300 mg kapseli, kova
strides pharma (cyprus) limited - gabapentin - kapseli, kova - 300 mg - gabapentiini
gabapentin strides 100 mg kapseli, kova
strides pharma (cyprus) limited - gabapentin - kapseli, kova - 100 mg - gabapentiini
vancomycin strides 125 mg kapseli, kova
strides pharma (cyprus) limited - vancomycin hydrochloride - kapseli, kova - 125 mg - vankomysiini
vancomycin strides 250 mg kapseli, kova
strides pharma (cyprus) limited - vancomycin hydrochloride - kapseli, kova - 250 mg - vankomysiini
oxaliplatin strides 5 mg/ml infuusiokuiva-aine, liuosta varten
strides arcolab international limited - oxaliplatinum - infuusiokuiva-aine, liuosta varten - 5 mg/ml - oksaliplatiini
mitoxantrone strides 2 mg/ml infuusiokonsentraatti, liuosta varten
strides arcolab international limited - mitoxantroni hydrochloridum - infuusiokonsentraatti, liuosta varten - 2 mg/ml - mitoksantroni
kauliv
strides pharma (cyprus) limited - teriparatidi - osteoporosis; osteoporosis, postmenopausal - kalsiumin homeostaasi - kauliv is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.
edistride
astrazeneca ab - dapagliflosiinipropaanidiolimonohydraatti - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - diabeetilla käytettävät lääkkeet - type 2 diabetes mellitusedistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. lisäksi muiden lääkkeiden hoitoon tyypin 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 ja 5. heart failureedistride is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseedistride is indicated in adults for the treatment of chronic kidney disease.
irinotecan mylan 20 mg/ml infuusiokonsentraatti, liuosta varten
mylan hospital as - irinotecani hydrochloridum trihydricum - infuusiokonsentraatti, liuosta varten - 20 mg/ml - irinotekaani